Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Pfizer › A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give ...

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that ...

Wall Street closed sharply higher on Monday, driven by strong rebounds in major artificial intelligence (AI) and technology ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...